Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE III STUDY OF BENMELSTOBART INJECTION IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY SEQUENTIAL COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES VERSUS TISLELIZUMAB INJECTION IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER2024.12.27
-
VOLUNTARY ANNOUNCEMENT - PERMISSION OBTAINED TO SUBMIT MARKETING APPLICATION FOR THE INDICATION OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR TREATMENT OF ADVANCED ALVEOLAR SOFT PART SARCOMA2024.12.19
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE III STUDY OF BENMELSTOBART INJECTION WITH OR WITHOUT ANLOTINIB HYDROCHLORIDE CAPSULES AS CONSOLIDATION THERAPY AFTER CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER2024.12.18
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "ERIBULIN MESILATE INJECTION"2024.12.11
-
VOLUNTARY ANNOUNCEMENT - ENTERING INTO GLOBAL COLLABORATION AGREEMENT WITH BIOSION AND ACLARIS THERAPEUTICS2024.12.05
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 20242024.12.02
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR THE INDICATION OF TREATMENT FOR ENDOMETRIAL CANCER2024.11.27
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA2024.11.21